The metabolism and genotoxicity of tamoxifen.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Progress in clinical and biological research

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 9108603
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen.

  1996cited by this paper
• Tamoxifen induces short-term cumulative DNA damage and liver tumors in rats: promotion by phenobarbital.

  1995cited by this paper
• Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.

  1995cited by this paper
• Evidence from 32P-postlabeling and the use of pentachlorophenol for a novel metabolic activation pathway of diethylstilbestrol and its dimethyl ether in mouse live: likely alpha-hydroxylation of ethyl group(s) followed by sulfate conjugation.

  1995cited by this paper
• Tamoxifen therapy and carcinogenic risk.

  1995cited by this paper
• 32P-postlabelled DNA adducts in liver obtained from women treated with tamoxifen.

  1995cited by this paper
• Species differences in the covalent binding of [14C]tamoxifen to liver microsomes and the forms of cytochrome P450 involved.

  1995cited by this paper
• Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats.

  1995cited by this paper
• Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen.

  1995cited by this paper
• DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumour formation.

  1995cited by this paper
• Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.

  1995cited by this paper
• Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts.

  1995cited by this paper
• Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen.

  1995cited by this paper
• Peroxidase activation of 4-hydroxytamoxifen to cause DNA damage in vitro.

  1995cited by this paper
• DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro.

  1995cited by this paper
• DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems.

  1994cited by this paper
• A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes.

  1994cited by this paper
• Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

  1994cited by this paper
• Strong intensification of mouse hepatic tamoxifen DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol.

  1994cited by this paper
• Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats.

  1994cited by this paper
• Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes.

  1994cited by this paper
• alpha-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes.

  1994cited by this paper
• Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s.

  1994cited by this paper
• The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat.

  1993cited by this paper
• Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats.

  1993cited by this paper
• High performance liquid chromatography of tamoxifen and metabolites in plasma and tissues.

  1993cited by this paper
• Induction of CYP2B1 and 3A1, and associated monoxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice.

  1993cited by this paper
• Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats.

  1993cited by this paper
• Induction of covalent DNA adducts in rodents by tamoxifen.

  1992cited by this paper
• Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells.

  1992cited by this paper
• Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes.

  1991cited by this paper
• Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation.

  1991cited by this paper
• Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.

  1991cited by this paper
• Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers.

  1989cited by this paper
• Species-specific pharmacology of antiestrogens: role of metabolism.

  1987cited by this paper
• The pharmacology and clinical uses of tamoxifen.

  1984cited by this paper
• Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers.

  1980cited by this paper
• Peroxidase activity in glands and stroma of human endometrium.

  1980cited by this paper

• Tamoxifen treatment failure in cancer and the nonlinear dynamics of TGFbeta.

  2004cites this paper
• Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling.

  2000cites this paper
• Estrogenic Genes through Chromatin Remodeling Breast Cancer Cell Line Irreversibly Inhibits the Expression of Long-Term Hydroxytamoxifen Treatment of an MCF-7-derived Updated

  2000cites this paper
• Toxicology of Estrogens and Antiestrogens

  1999cites this paper
• Steroidal and nonsteroidal oestrogen antagonists in breast cancer: basic and clinical appraisal.

  1998cites this paper